- Home
- HEPS vs VOR Comparison
HEPS vs VOR Comparison
Compare HEPS & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HEPS | VOR |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.0M | 767.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HEPS | VOR |
|---|---|---|
| Price | $2.84 | $15.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $3.07 | ★ $45.33 |
| AVG Volume (30 Days) | 229.2K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.29 | N/A |
| Revenue Next Year | $27.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $0.13 |
| 52 Week High | $3.30 | $49.95 |
Technical Indicators
Market Signals| Indicator | HEPS | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 57.96 | 50.07 |
| Support Level | $2.53 | $11.38 |
| Resistance Level | $2.85 | $16.88 |
| Average True Range (ATR) | 0.07 | 1.40 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 66.13 | 20.32 |
Price Performance
Historical ComparisonAbout HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.